Polycythemia Vera · Ropeginterferon alfa-2b (Besremi) for PV — 1L cytoreductive
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-ROPEGINTERFERON-PV |
| ID | IND-PV-1L-ROPEGINTERFERON |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-PV |
| Sources | SRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025 SRC-PROUD-PV-GISSLINGER-2020 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 1L for younger fit PV with disease-modification goal. Ukraine access constraint dominant.
Used By
Algorithms
ALGO-ET-2L- ALGO-ET-2LALGO-PV-1L- ALGO-PV-1LALGO-PV-2L- ALGO-PV-2L